Special Issue "Early Detection of Cancer and Its Recurrence – Technologies and Biomarkers to Enhance Clinical Translation"
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 2017
Early detection of cancer and earlier detection of its recurrence is of paramount importance to improve overall outcomes. Here we are interested not only in the biology and biomarkers related to earlier detection (including both circulating and tumor-specific markers) but also in advancing technologies to assist with translating these findings to clinical settings. In addition, many novel ideas fail to have clinical uptake for various reasons including due to cost, time, or complex workflows that are difficult to implement in a clinical setting. Articles of interest will thus span from technological improvements and advancements that may make the translational process to clinical applicability faster, easier, and/or less costly to specific markers or panels of markers that help to predict the presence of cancer or signify a change in the tumor behavior. In addition, articles that deal with prediction of treatment resistance (either prior to starting initial treatment or while on treatment) are also welcome, with emphasis on immunotherapies. Of special interest are findings that have applicability towards several cancers (multi-cancer or pan-cancer), though studies that are focused on single cancer types are also welcomed.
Dr. Rajan P. Kulkarni
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- early detection
- novel technology
- cancer recurrence
- treatment response
- treatment resistance
- clinical translation